The combination therapy of PD-L1 blockade and IDO inhibitor can improve anti-tumor effects by increasing the frequency of IL-2-producing and proliferating polyfunctional T cells within the tumor, and prolonging the duration and frequency of peripheral tumor-reactive lymphocytes at a later stage. Here, IDO1 is linked to neoplasm.